Results 161 to 170 of about 49,720 (263)
Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm +2 more
wiley +1 more source
Elucidating the role of the tumor suppressor Protein Phoshatase 2A in Chronic Myeloid Leukemia.
Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases and is involved in the regulation of cell homeostasis through the negative regulation of signaling pathways initiated by protein kinases.
Neviani, Paolo
core
Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”?
American Journal of Hematology, EarlyView.
Sudhir Tauro, Ayalew Tefferi
wiley +1 more source
Objective The unknown pathophysiology and the lack of specific features for systemic juvenile idiopathic arthritis and adult‐onset Still disease (collectively known as Still disease; SD) delay diagnosis and appropriate treatment. The goal of this study was to identify features and mechanisms that distinguish SD from other systemic autoinflammatory ...
Yvonne M. Mueller +16 more
wiley +1 more source
Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen +14 more
wiley +1 more source
Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan +8 more
wiley +1 more source
Carrier‐free self‐assembled nanomedicine for combination‐therapy of acute myeloid leukemia
CPDS combines drugs with three different mechanisms of action to achieve a multi‐mechanism combination therapy for AML by directly killing tumor cells and activating anti‐tumor immunity. Abstract As the main acute myeloid leukemia (AML) clinical treatment, the chemotherapy alone cannot meet the clinical therapeutic needs due to the high heterogeneity ...
Meihong Chai +14 more
wiley +1 more source
Tackling cancer stemness with nanotechnology in the era of precision medicine
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo +9 more
wiley +1 more source
A modular, de novo α/β‐peptide design strategy allows fine‐tuning of ligand properties, resulting in multivalent ligands that simultaneously target separate binding sites on the protein surface. ABSTRACT Protein‐protein interactions that regulate gene expression in the nucleus are increasingly recognized as potential therapeutic targets but present ...
Márk V. Tresztián +4 more
wiley +1 more source

